Clinical effects of chemotherapy combined with Bevacizumab and Olaparib in treating advanced ovarian cancer and its effect on serum tumor markers and T-lymphocyte functions
The combined use of conventional chemotherapy, bevacizumab, and olaparib demonstrates significant clinical efficacy in the treatment of advanced ovarian cancer, which can improve cellular immune function, lower tumor marker levels.
Authors
- Dan Liu (ORCID: https://orcid.org/0000-0002-9971-2264)
- Lin He (ORCID: https://orcid.org/0000-0003-1079-1195)
- Zhifeng Yang
- Ying Jiao
Institutions
- Baoding People's Hospital (CN)
Publication Details
- Journal
- Pakistan Journal of Medical Sciences
- Published
- 2025-06-02
- DOI
- https://doi.org/10.12669/pjms.41.6.10843
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00